References
Adgey AAJ, Allen JD, Geddes JS, James RGG, Webb SW, et al. Acute phase of myocardial infarction. Lancet 2: 501–504, 1971
Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction: implications for the use of lidocaine. Circulation 84 (Suppl. II): 11–712, 1991
Bromage PR, Robson JG. Concentrations of lignocaine in the blood after intravenous, intramuscular epidural and endotracheal administration. Anaesthesia 16: 461–478, 1961
Cox JR, Roberts R, Ambos HD, Oliver GC, Sobel BE. Relations between enzymatically estimated myocardial infarct size and early ventricular dysrhythmia. Circulation 53 (Suppl. I): I150–I155, 1976
Cusson J, Nattel S, Matthews C, Talajic M, Lawand S. Age-dependent lidocaine disposition in patients with acute myocardial infarction. Clinical Pharmacology and Therapeutics 37: 381–385, 1985
De Soyza N, Meacham D, Murphy ML, Kane JJ, Doherty JE, et al. Evaluation of warning arrhythmias before paroxysmal ventricular tachycardia during acute myocardial infarction in man. Circulation 60: 815–818, 1979
Dunn HM, McComb JM, Kinney CD, Campbell NPS, Shanks RG. Prophylactic lidocaine in the early phase of suspected myocardial infarction. American Heart Journal 110: 353–362, 1985
Fulton M, Julian DG, Oliver MF. Sudden death and myocardial infarction. Circulation 40 (Suppl. 4): 182–193, 1969
Goldman L, Batsford WP. Risk-benefit stratification as a guide to lidocaine prophylaxis of primary ventricular fibrillation in acute myocardial infarction: an analytic review. Yale Journal of Biology and Medicine 52: 455–466, 1979
Harrison DC, Berte LE. Should prophylactic antiarrhythmic drug therapy be used in acute myocardial infarction?. Journal of the American Medical Association 247: 2019–2021, 1982
Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Archives of Internal Medicine 149: 2694–2698, 1989
Horwitz RI, Feinstein AR. Improved observational method for studying therapeutic efficacy. Suggestive evidence that lidocaine prophylaxis prevents death in acute myocardial infarction. Journal of the American Medical Association 246: 2455–2459, 1981
Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiological Reviews 69: 1049–1169, 1989
Jewitt DE, Kishon Y, Thomas M. Lignocaine in the management of arrhythmias after acute myocardial infarction. Lancet 1: 266–270, 1968
Julian DG, Valentine PA, Miller GG. Disturbances of rate, rhythm and conduction in acute myocardial infarction. American Journal of Medicine 37: 915–927, 1964
Kertes P, Hunt D. Prophylaxis of primary ventricular fibrillation in acute myocardial infarction: the case against lignocaine. British Heart Journal 52: 241–247, 1984
Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. New England Journal of Medicine 313: 1105–1110, 1985
Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation: a double-blind, randomized study of 212 consecutive patients. New England Journal of Medicine 291: 1324–1326, 1974
Lie KI, Wellens HJJ, Downar E, Durrer D. Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation 52: 755–759, 1975
Lown B, Fakhro AM, Hood WB. The coronary care unit. New perspectives and directions. Journal of the American Medical Association 199: 188–198, 1967
MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. Journal of the American Medical Association 260: 1910–1916, 1988
Nattel S, Gagne G, Pineau M. The pharmacokinetics of lignocaine and β-adrenoceptor antagonists in patients with acute myocardial infarction. Clinical Pharmacokinetics 13: 293–316, 1987
Nattel S, Waters D. What is an antiarrhythmic drug? From clinical trials to fundamental concepts. American Journal of Cardiology 66: 96–99, 1990
Noneman JW, Rogers JF. Lidocaine prophylaxis in acute myocardial infarction. Medicine 57: 501–515, 1978
Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction. In Braunwald E (Ed.) Heart disease, 4th ed., Vol. 2, pp. 1200–1291, W.B. Saunders Company, Philadelphia, 1992
Pfeifer HJ, Greenblatt DJ, Koch-Weiser J. Clinical use and toxicity of intravenous lidocaine. American Heart Journal 92: 168–173, 1976
Pitt A, Lipp H, Anderson ST. Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet 1: 612–616, 1971
Ribner HS, Isaacs ES, Frishman WH. Lidocaine prophylaxis against ventricular fibrillation in acute myocardial infarction. Progress in Cardiovascular Diseases 21: 287–313, 1979
Roberts R, Husain A, Ambos HD, Oliver GC, Cox JR, et al. Relation between infarct size and ventricular arrhythmia. British Heart Journal 37: 1169–1175, 1975
Volpi A, Maggioni A, Franzosi MG, Pampailona S, Mauri F, et al. In-hospital prognosis of patients with acute myocardial infarction complicated by primary ventricular fibrillation. New England Journal of Medicine 317: 257–261, 1987
Wyse G, Kellen J, Rademaker AW. Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. Journal of the American College of Cardiology 12: 507–513, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nattel, S., Arenal, A. Antiarrhythmic Prophylaxis after Acute Myocardial Infarction. Drugs 45, 9–14 (1993). https://doi.org/10.2165/00003495-199345010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199345010-00002